<DOC>
	<DOC>NCT01260181</DOC>
	<brief_summary>This single arm, open-label study will evaluate the efficacy and safety of erlotinib (Tarceva) in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations.</brief_summary>
	<brief_title>A Study of Erlotinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>Locally advanced or metastatic NSCLC with EGFR mutations Measurable disease according to RECIST criteria Adequate hematological, renal and liver function Previous chemotherapy or therapy against EGFR for metastatic disease Symptomatic cerebral metastases Preexisting disease of the lung parenchyma such as lung fibrosis, lymphangitic carcinomatosis History of another malignancy except for carcinoma insitu of the cervix, adequately treated basal cell skin carcinoma, or radically treated prostate carcinoma with good prognosis Concomitant use of coumarins</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>